Last updated Jun 6, 2026
Aurobindo Pharma
Evidence Sources
5
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
1
Confidence Coverage
69%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Neurology
- Antiepileptic
Highest priority development: Aurobindo Pharma's Lamotrigine Approval Signals Market Disruption in Antiepileptics
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 69%
Active Signals
1
Investigate Priority
0
Opportunity Score
15
Buyer Quality
2 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 6, 2026Score 15Aurobindo Pharma's Lamotrigine ANDA Submission Receives AP Status
Neurology · Antiepileptic
Related Assets
Portfolio asset pages with evidence-based assessments.
- Aurobindo Pharma's Lamotrigine Approval Signals Market Disruption in AntiepilepticsModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — LAMOTRIGINE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — LAMOTRIGINE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — LAMOTRIGINE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — LAMOTRIGINE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Aurobindo Pharma's Lamotrigine Approval Signals Market Disruption in AntiepilepticsModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Aurobindo Pharma right now?
- Which regulatory precedents should Aurobindo Pharma monitor in Neurology and Antiepileptic?
- How does Aurobindo Pharma's Lamotrigine Approval Signals Market Disruption in Antiepileptics compare to the nearest competitive programs?
- What signals require immediate investigation for Aurobindo Pharma?
- Summarize the strategic implications of recent developments for Aurobindo Pharma.
- Where is the greatest uncertainty in Aurobindo Pharma's competitive positioning?